Page 61 - Read Online

Page 12 of 13 Méndez-Sánchez et al. Hepatoma Res 2020;6:5 I http://dx.doi.org/10.20517/2394-5079.2019.29

43. Duque Correa MA, Rojas López M. Activación alternativa del macrófago: La diversidad en las respuestas de una célula de la
inmunidad innata ante la complejidad de los eventos de su ambiente. Inmunologia 2007;26:73-86. (in Spanish)
44. Leclercq S, Cani PD, Neyrinck AM, Stärkel P, Jamar F, et al. Role of intestinal permeability and inflammation in the biological and
behavioral control of alcohol-dependent subjects. Brain Behav Immun 2012;26:911-8.
45. Grabherr F, Grander C, Adolph TE, Wieser V, Mayr L, et al. Ethanol-mediated suppression of IL-37 licenses alcoholic liver disease.
Liver Int 2018;38:1095-101.
46. Zhao JJ, Pan QZ, Pan K, Weng DS, Wang QJ, et al. Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role
for CD57+ NK cells. Sci Rep 2015;4:5177.
47. Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol
2017;14:527-39.
48. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and
TLR4. Cancer Cell 2012;21:504-16.
49. Toyoda H, Komurasaki T, Uchida D, Takayama Y, Isobe T, et al. Epiregulin. A novel epidermal growth factor with mitogenic activity
for rat primary hepatocytes. J Biol Chem 1995;270:7495-500.
50. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced
liver injury in mice. Hepatology 2001;34:101-8.
51. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to
ethanol. Gastroenterology 1995;108:218-24.
52. Yan G, Wang X, Sun C, Zheng X, Wei H, et al. Chronic alcohol consumption promotes diethylnitrosamine-induced
hepatocarcinogenesis via immune disturbances. Sci Rep 2017;7:2567.
53. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through
senescence secretome. Nature 2013;499:97-101.
54. Xie G, Wang X, Liu P, Wei R, Chen W, et al. Distinctly altered gut microbiota in the progression of liver disease. Oncotarget
2016;7:19355-66.
55. Grąt M, Krasnodębski M, Patkowski W, Wronka KM, Masior Ł, et al. Relevance of pre-transplant α-fetoprotein dynamics in liver
transplantation for hepatocellular cancer. Ann Transplant 2016;21:115-24.
56. Ren Z, Li A, Jiang J, Zhou L, Yu Z, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early
hepatocellular carcinoma. Gut 2019;68:1014-23.
57. Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med
2019;25:377-88.
58. Fox JG, Feng Y, Theve EJ, Raczynski AR, Fiala JLA, et al. Gut microbes define liver cancer risk in mice exposed to chemical and
viral transgenic hepatocarcinogens. Gut 2010;59:88-97.
59. Rogers AB. Distance burning: how gut microbes promote extraintestinal cancers. Gut Microbes 2011;2:52-7.
60. Huang Y, Fan XG, Wang ZM, Zhou JH, Tian XF, et al. Identification of helicobacter species in human liver samples from patients with
primary hepatocellular carcinoma. J Clin Pathol 2004;57:1273-7.
61. Temko JE, Bouhlal S, Farokhnia M, Lee MR, Cryan JF, et al. The microbiota, the gut and the brain in eating and alcohol use disorders:
a “ménage à trois”? Alcohol Alcohol 2017;52:403-13.
62. Bishehsari F, Magno E, Swanson G, Desai V, Voigt RM, et al. Alcohol and gut-derived inflammation. Alcohol Res 2017;38:163-71.
63. Ling Z, Liu X, Cheng Y, Jiang X, Jiang H, et al. Decreased diversity of the oral microbiota of patients with hepatitis b virus-induced
chronic liver disease: a pilot project. Sci Rep 2015;5:17098.
64. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
65. Bajaj JS, Sterling RK, Betrapally NS, Nixon DE, Fuchs M, et al. HCV eradication does not impact gut dysbiosis or systemic
inflammation in cirrhotic patients. Aliment Pharmacol Ther 2016;44:638-43.
66. Maggio R, Viscomi C, Andreozzi P, D’Ettorre G, Viscogliosi G, et al. Normocaloric low cholesterol diet modulates Th17/Treg balance
in patients with chronic hepatitis C virus infection. PLoS One 2014;9:e112346.
67. Preveden T, Scarpellini E, Milić N, Luzza F, Abenavoli L. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev
Gastroenterol Hepatol 2017;11:813-9.
68. Aly AM, Adel A, El-Gendy AO, Essam TM, Aziz RK. Gut microbiome alterations in patients with stage 4 hepatitis C. Gut Pathog
2016;8:42.
69. Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, et al. Expansion of intestinal Prevotella copri correlates with enhanced
susceptibility to arthritis. Elife 2013;2:e01202.
70. Sousa GM, Oliveira IS, Andrade LJO, Sousa-Atta MLB, Paraná R, et al. Serum levels of Th17 associated cytokines in chronic
hepatitis C virus infection. Cytokine. 2012;60:138-42.
71. Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap--bile acids in metabolic control. Nat Rev Endocrinol 2014;10:488-98.
72. Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol
Hepatol 2018;15:111-28.
73. Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter
OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 2006;290:G1124-30.
74. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is
transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001;276:28857-65.
75. Anwer MS. Intracellular signaling by bile acids. J Biosci (Rajshari) 2012;20:1-23.
76. Jung IH, Choi JHK, Chung YY, Lim GL, Park YN, et al. Predominant activation of JAK/STAT3 pathway by interleukin-6 is implicated
in hepatocarcinogenesis. Neoplasia 2015;17:586-97.